Latest / Decera Clinical Education Oncology Podcast
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including:
Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or placebo maintenance for 2 years in patients with measurable stage III/IVA, stage IVB, or recurrent endometrial cancer.
Phase III ENGOT-EN6/GOG-3031/RUBY trial of carboplatin and paclitaxel with or without dostarlimab followed by dostarlimab or placebo…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.